Katie Barnes
Family · Fairview, TNNPI 1023046794
Payments from drug & device makers
Across 366 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$888
- AbbVie$748
- AstraZeneca$577
- Biohaven Pharmaceutical Holding Company Ltd.$487
- Pfizer$282
- plus $2K from 25 others
What the payments were for
- Travel & lodging$3065%
- Food & beverage$6,46395%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 118 | $2,036 |
| Lilly USA, LLC | 56 | $888 |
| AbbVie | 46 | $748 |
| AstraZeneca(2 entities) | 32 | $577 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $487 |
| Pfizer | 15 | $282 |
| GSK | 20 | $279 |
| Bayer | 11 | $237 |
| Xeris Pharmaceuticals, Inc. | 9 | $185 |
| Abbott | 8 | $154 |
| Exact Sciences | 7 | $130 |
| Sumitomo Pharma America, Inc. | 7 | $127 |
| Boehringer Ingelheim | 5 | $109 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Amgen | 5 | $78 |
| Shield Therapeutics Inc | 3 | $51 |
| Stryker | 1 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Harmony Biosciences LLC | 1 | $24 |
| Agios Pharmaceuticals, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| VBI Vaccine (delaware) Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$306
- RYBELSUS$121
- ZEPBOUND$117
- MOUNJARO$103
How this compares
$6,768 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 86 | $112,267 |
| OzempicSemaglutide | 66 | $106,392 |
| FarxigaDapagliflozin Propanediol | 79 | $73,707 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $67,388 |
| EliquisApixaban | 51 | $41,396 |
| GemtesaVibegron | 52 | $37,370 |
| Repatha SureclickEvolocumab | 46 | $36,920 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $33,854 |
| MyrbetriqMirabegron | 34 | $31,821 |
| UbrelvyUbrogepant | 22 | $28,573 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $25,495 |
| XareltoRivaroxaban | 17 | $24,605 |
| LinzessLinaclotide | 19 | $22,955 |
| RybelsusSemaglutide | 11 | $19,107 |
| JardianceEmpagliflozin | 21 | $16,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,036 | $125,49977 claims |
| Lilly USA, LLCMounjaro | $888 | $112,26786 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $577 | $99,202102 claims |
| GSKTrelegy Ellipta | $279 | $67,38890 claims |
| AbbVieUbrelvy, Linzess, Qulipta | $748 | $63,84453 claims |
| PfizerEliquis | $282 | $41,39651 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $127 | $37,37052 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $31,82134 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $109 | $22,17335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Fairview
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.